Physician profile
David S Kramer
NPI 1407845886
$2,092.00
in general payments reported to CMS, 2019-2025
19 companies · $73.93 in 2025
The $73.93 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $298 · 2021: $254 · 2022: $155 · 2023: $233 · 2024: $339 · 2025: $73.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $386.35 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $320.65 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $272.45 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $252.87 | 2020-2024 | Camzyos, Eliquis |
| Lilly USA, LLC | $124.35 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $119.49 | 2024 | Inpefa |
| Abbott Laboratories | $108.22 | 2019 | |
| Boston Scientific Corporation | $101.27 | 2019 | |
| Exact Sciences Corporation | $97.58 | 2023-2025 | Cologuard Collection Kit |
| Zimmer Biomet Holdings, INC. | $86.11 | 2019 | |
| Merck Sharp & Dohme LLC | $56.26 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $33.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.51 | 2022-2023 | Seglentis, Livalo |
| Janssen Biotech, INC. | $22.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.21 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.13 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $14.85 | 2019 | |
| Astellas Pharma US INC | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.